mAbxience
Tracked across 1 events · 8 articles · First seen Sep 18, 2026 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: mAbxience is the development and manufacturing lead for the emicizumab biosimilar, gaining pipeline expansion into hemophilia A and rare diseases and reinforcing its biosimilars platform.
Sep 18, 2026 · 8 articles
95
mAbxience signed collaboration agreement Novartis — SandozmAbxience Sandoz...
70
mAbxience granted exclusive commercialization rights Novartis — SandozmAbxience Sandoz...
60
mAbxience took development manufacturing responsibilitymAbxience Sandoz...
ERGEN INTELLIGENCE
Track mAbxience live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard